Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)

INTRODUCTION: This study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SAR(Asp)-Mix) with European-approved insulin aspart mix 70/30 − NovoMix® 30 (NN-Mix) in people with type 1 (T1D) or type 2 diabetes (T2D). METHODS: This 26-week, open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Aravind, S. R., Singh, Kiran P., Aquitania, Grace, Mogylnytska, Liliia, Zalevskaya, Alsu G., Matyjaszek-Matuszek, Beata, Wernicke-Panten, Karin, Nguyên-Pascal, My-Liên, Pierre, Suzanne, Rotthaeuser, Baerbel, Kramer, Daniel, Mukherjee, Bhaswati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008602/
https://www.ncbi.nlm.nih.gov/pubmed/35420397
http://dx.doi.org/10.1007/s13300-022-01255-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008602/
https://www.ncbi.nlm.nih.gov/pubmed/35420397
http://dx.doi.org/10.1007/s13300-022-01255-7

Ejemplares similares